Douglas Lane & Associates LLC Acquires 99,713 Shares of Moderna, Inc. (NASDAQ:MRNA)

Douglas Lane & Associates LLC grew its stake in Moderna, Inc. (NASDAQ:MRNA - Free Report) by 12.9% during the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 873,517 shares of the company's stock after purchasing an additional 99,713 shares during the quarter. Douglas Lane & Associates LLC owned approximately 0.23% of Moderna worth $24,764,000 as of its most recent filing with the SEC.

A number of other hedge funds have also bought and sold shares of MRNA. Wilmington Savings Fund Society FSB grew its holdings in Moderna by 295.0% in the 4th quarter. Wilmington Savings Fund Society FSB now owns 786 shares of the company's stock worth $33,000 after buying an additional 587 shares in the last quarter. Compass Planning Associates Inc acquired a new position in shares of Moderna during the fourth quarter valued at approximately $37,000. Venturi Wealth Management LLC increased its stake in shares of Moderna by 286.2% during the fourth quarter. Venturi Wealth Management LLC now owns 896 shares of the company's stock valued at $37,000 after acquiring an additional 664 shares during the period. Crowley Wealth Management Inc. acquired a new position in shares of Moderna during the fourth quarter valued at approximately $41,000. Finally, Itau Unibanco Holding S.A. increased its stake in shares of Moderna by 51.2% during the fourth quarter. Itau Unibanco Holding S.A. now owns 1,013 shares of the company's stock valued at $42,000 after acquiring an additional 343 shares during the period. 75.33% of the stock is currently owned by institutional investors and hedge funds.

Moderna Trading Down 4.0%

Shares of MRNA traded down $1.08 during mid-day trading on Thursday, hitting $26.19. 5,419,851 shares of the company traded hands, compared to its average volume of 8,229,486. Moderna, Inc. has a one year low of $23.15 and a one year high of $158.82. The business has a 50-day moving average of $26.23 and a 200 day moving average of $33.71. The stock has a market capitalization of $10.13 billion, a price-to-earnings ratio of -2.83 and a beta of 1.86.

Moderna (NASDAQ:MRNA - Get Free Report) last issued its quarterly earnings data on Thursday, May 1st. The company reported ($2.52) EPS for the quarter, topping analysts' consensus estimates of ($2.92) by $0.40. Moderna had a negative net margin of 110.04% and a negative return on equity of 28.74%. The business had revenue of $108.00 million for the quarter, compared to analyst estimates of $130.35 million. During the same period last year, the business posted ($3.07) earnings per share. The firm's quarterly revenue was down 35.3% on a year-over-year basis. As a group, analysts anticipate that Moderna, Inc. will post -9.61 earnings per share for the current year.

Analyst Ratings Changes

Several research analysts have issued reports on the company. JPMorgan Chase & Co. dropped their price target on Moderna from $33.00 to $26.00 and set an "underweight" rating on the stock in a report on Thursday, May 22nd. William Blair reaffirmed a "market perform" rating on shares of Moderna in a research note on Monday. Bank of America decreased their price target on shares of Moderna from $41.00 to $34.00 and set an "underperform" rating for the company in a report on Tuesday, February 11th. UBS Group cut their price objective on shares of Moderna from $78.00 to $70.00 and set a "buy" rating for the company in a research report on Friday, May 2nd. Finally, Royal Bank of Canada cut their price objective on shares of Moderna from $32.00 to $28.00 and set a "sector perform" rating for the company in a research report on Friday, May 2nd. Four analysts have rated the stock with a sell rating, fifteen have assigned a hold rating, three have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, Moderna presently has a consensus rating of "Hold" and an average price target of $53.58.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.